Premium
Interleukin‐2‐induced increase of a monoclonal b‐cell lymphocytosis. A novel In vivo interleukin‐2 effect?
Author(s) -
Tiberghien Pierre,
Racadot Evelyne,
Deschaseaux Marie L.,
Delain Martine,
Voillat Laurent,
Billot Maryse,
Flesch Michel,
Rozenbaum Annie,
Brandely Maud,
Cahn JeanYves,
Herve Patrick
Publication year - 1992
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19920515)69:10<2583::aid-cncr2820691031>3.0.co;2-i
Subject(s) - lymphocytosis , cd19 , medicine , population , monoclonal , lymphocyte , interleukin 2 , immunology , monoclonal antibody , aldesleukin , b cell , microbiology and biotechnology , cytokine , biology , immune system , antibody , environmental health
A 56‐year‐old man with refractory B‐cell lymphocytic non‐Hodgkin's lymphoma was treated in a Phase II study with interleukin‐2 (IL‐2) (Roussel‐Uclaf, Romainville, France). The patient had involvement of multiple lymph nodes and medullary and peripheral blood (3.6 × 10′ monoclonal CD19‐positive [CD19+] B‐lymphocytes/l). After a 5‐day cycle of IL‐2 treatment, an eightfold increase of the monoclonal CD19+ population was observed (27 × 10 9 monoclonal CD19+ cells). The lymphocytosis decreased dramatically during the second cycle (days 15 to 19) of IL‐2 treatment, resulting in 6 × 10 9 /l peripheral lymphocytes, with 5.5 × 10 9 B‐lymphocytes. As soon as day 20, peripheral B‐cells again increased considerably, with 32 × 10 9 CD19+ cells/l at day 27. The CD19+ population remained monoclonal as assessed by kappa/lambda cell‐surface phenotyping and kappa gene rearrangement evaluation. Kinetics of the monoclonal B‐lymphocyte response to IL‐2 paralleled the natural killer/lymphokine‐activated killer and T‐cell response, with a 4‐day latency period, suggesting an indirect enhancing effect of IL‐2. Before and during IL‐2 treatment, peripheral B‐lymphocytes never expressed detectable levels of the p55 IL‐2 receptor. However, the p75 IL‐2 receptor was expressed significantly in the IL‐8‐responsive monoclonal B‐cell population. Tumor necrosis factor alpha, a known ( in vitro ) B‐cell tumor growth factor, reached high serum levels during IL‐2 treatment. Response evaluation at day 45 showed stability of the lymph node involvement and the marrow lymphocyte infiltrate. At day 45, peripheral B‐cell lymphocytosis was 7.5 × 10 9 /l. To the knowledge of the authors, this is the first report of an in vivo IL‐induced reversible increase of peripheral monoclonal B‐cell lymphocytosis.